94 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
, global pipeline strategy and precision medicine at Novartis Oncology, or Novartis, a global pharmaceutical company from October 2018 to February 2021 … early-stage portfolio and diagnostics strategy for oncology. Earlier in his career at Novartis, Mr. Chee served as vice president – global head
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
SUPPORT DEVELOPMENT STRATEGY Growing body of evidence in MDS and AML patients with RARA overexpression $45M FINANCING ADDS TO STRONG CORPORATE … with RARA overexpression supports development strategy 1Data presented at ASH 2017, and Syros Data on File; 2de Botton S., et al. Blood Advances 2022
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
regimen as a salvage strategy in patients in the control arm who do not respond to venetoclax and azacitidine. The primary endpoint of the trial … our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management
8-K
EX-99.1
k9lq6dfj77hxzld7i
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
xfp4r fz5ulf5pa
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
13jkgunv2wa
2 Oct 23
Cost Associated with Exit or Disposal Activities
8:49am
8-K
EX-99.1
djp7oq x01
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
vn16zt
25 May 23
Regulation FD Disclosure
5:10pm
424B5
s7w09igg hqkc
1 May 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
sgzllnzj4kf6
12 Dec 22
Regulation FD Disclosure
7:48am